The DOI matches its Crossref record; 179 of the 179 references it cites were found in a registry or an index.
Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline
Abstract
PURPOSE: To provide evidence-based recommendations on the treatment of multiple myeloma to practicing physicians and others. METHODS: ASCO and Cancer Care Ontario convened an Expert Panel of medical oncology, surgery, radiation oncology, and advocacy experts to conduct a literature search, which included systematic reviews, meta-analyses, randomized controlled trials, and some phase II studies published from 2005 through 2018. Outcomes of interest included survival, progression-free survival, response rate, and quality of life. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS: The literature search identified 124 relevant studies to inform the evidence base for this guideline. RECOMMENDATIONS: Evidence-based recommendations were developed for patients with multiple myeloma who are transplantation eligible and those who are ineligible and for patients with relapsed or refractory disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70442-5 · Cited by 4,978
Self-citationKumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citationInternational Staging System for Multiple Myeloma
Greipp, P. R., Miguel, J. S., Durie, B. G. M., Crowley, J. J., Barlogie, B., Bladé, J., Boccadoro, M., Child, J. A., Avet-Loiseau, H., Kyle, R. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.242 · Cited by 2,974
International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Self-citationAttal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
Richardson, P. G., Sonneveld, P., Schuster, M. W., Irwin, D., Stadtmauer, E. A., Facon, T., Harousseau, J.-L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043445 · Cited by 2,491
Palumbo, A., Avet-Loiseau, H., Oliva, S., Lokhorst, H. M., Goldschmidt, H., Rosinol, L., Richardson, P., Caltagirone, S., Lahuerta, J. J., Facon, T., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.2267 · Cited by 2,210
Self-citationFerrell, B. R., Temel, J. S., Temin, S., Alesi, E. R., Balboni, T. A., Basch, E. M., Firn, J. I., Paice, J. A., Peppercorn, J. M., Phillips, T., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.1474 · Cited by 2,117
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899
Understanding the Treatment Preferences of Seriously Ill Patients
Fried, T. R., Bradley, E. H., Towle, V. R., & Allore, H. (2002) · New England Journal of Medicine · doi:10.1056/nejmsa012528 · Cited by 1,522
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Palumbo, A., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., Beksac, M., Spicka, I., Hungria, V., Munder, M., Mateos, M. V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606038 · Cited by 1,522
BladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
Self-citationDaratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., Rabin, N., Orlowski, R. Z., Komarnicki, M., Suzuki, K., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607751 · Cited by 1,445 · cited 1×
“Most clinical trials have used the IMWG criteria for progressive disease, which includes criteria for both biochemical and clinical relapse for initiating therapy.(53,55,58,95,107,112)”
MethodCarfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411321 · Cited by 1,332
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Lonial, S., Dimopoulos, M., Palumbo, A., White, D., Grosicki, S., Spicka, I., Walter-Croneck, A., Moreau, P., Mateos, M.-V., Magen, H., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505654 · Cited by 1,322
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Attal, M., Lauwers-Cances, V., Hulin, C., Leleu, X., Caillot, D., Escoffre, M., Arnulf, B., Macro, M., Belhadj, K., Garderet, L., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611750 · Cited by 1,257
Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Lauwers-Cances, V., Marit, G., Caillot, D., Moreau, P., Facon, T., Stoppa, A. M., Hulin, C., Benboubker, L., Garderet, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114138 · Cited by 1,155
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Moreau, P., Masszi, T., Grzasko, N., Bahlis, N. J., Hansson, M., Pour, L., Sandhu, I., Ganly, P., Baker, B. W., Jackson, S. R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516282 · Cited by 1,060
Self-citationRajkumar, S. V., Harousseau, J.-L., Durie, B., Anderson, K. C., Dimopoulos, M., Kyle, R., Blade, J., Richardson, P., Orlowski, R., Siegel, D., et al. (2011) · Blood · doi:10.1182/blood-2010-10-299487 · Cited by 1,036
Self-citationDaratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
Mateos, M.-V., Dimopoulos, M. A., Cavo, M., Suzuki, K., Jakubowiak, A., Knop, S., Doyen, C., Lucio, P., Nagy, Z., Kaplan, P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714678 · Cited by 988
Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Harousseau, J.-L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.-G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032290 · Cited by 984
Moreau, P., Pylypenko, H., Grosicki, S., Karamanesht, I., Leleu, X., Grishunina, M., Rekhtman, G., Masliak, Z., Robak, T., Shubina, A., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70081-x · Cited by 920
Schnipper, L. E., Davidson, N. E., Wollins, D. S., Tyne, C., Blayney, D. W., Blum, D., Dicker, A. P., Ganz, P. A., Hoverman, J. R., Langdon, R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.6706 · Cited by 912
Facon, T., Mary, J. Y., Hulin, C., Benboubker, L., Attal, M., Pegourie, B., Renaud, M., Harousseau, J. L., Guillerm, G., Chaleteix, C., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61537-2 · Cited by 869
Dimopoulos, M. A., Moreau, P., Palumbo, A., Joshua, D., Pour, L., Hájek, R., Facon, T., Ludwig, H., Oriol, A., Goldschmidt, H., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00464-7 · Cited by 857
How Quickly Do Systematic Reviews Go Out of Date? A Survival Analysis
Shojania, K. G., Sampson, M., Ansari, M. T., Ji, J., Doucette, S., & Moher, D. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-4-200708210-00179 · Cited by 838
Sonneveld, P., Schmidt-Wolf, I. G. H., van der Holt, B., el Jarari, L., Bertsch, U., Salwender, H., Zweegman, S., Vellenga, E., Broyl, A., Blau, I. W., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.6820 · Cited by 824
Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
Benboubker, L., Dimopoulos, M. A., Dispenzieri, A., Catalano, J., Belch, A. R., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402551 · Cited by 793 · cited 3×
“gov identifier: NCT00689936) in transplant-ineligible patients.(40) Continuous lenalidomide-dexamethasone was also associated with an improvement in OS compared with MPT.”
BackgroundMethodResultSan-Miguel, J. F., Hungria, V. T. M., Yoon, S.-S., Beksac, M., Dimopoulos, M. A., Elghandour, A., Jedrzejczak, W. W., Günther, A., Nakorn, T. N., Siritanaratkul, N., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70440-1 · Cited by 791
The quality of life scale (QOLS): reliability, validity, and utilization
Burckhardt (2003) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-1-60 · Cited by 789
Autologous Transplantation and Maintenance Therapy in Multiple Myeloma
Palumbo, A., Cavallo, F., Gay, F., Di Raimondo, F., Ben Yehuda, D., Petrucci, M. T., Pezzatti, S., Caravita, T., Cerrato, C., Ribakovsky, E., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402888 · Cited by 778
Palumbo, A., Bringhen, S., Mateos, M.-V., Larocca, A., Facon, T., Kumar, S. K., Offidani, M., McCarthy, P., Evangelista, A., Lonial, S., et al. (2015) · Blood · doi:10.1182/blood-2014-12-615187 · Cited by 775
Self-citationContinuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma
Palumbo, A., Hajek, R., Delforge, M., Kropff, M., Petrucci, M. T., Catalano, J., Gisslinger, H., Wiktor-Jędrzejczak, W., Zodelava, M., Weisel, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112704 · Cited by 741
McCarthy, P. L., Holstein, S. A., Petrucci, M. T., Richardson, P. G., Hulin, C., Tosi, P., Bringhen, S., Musto, P., Anderson, K. C., Caillot, D., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.6679 · Cited by 698
Schnipper, L. E., Davidson, N. E., Wollins, D. S., Blayney, D. W., Dicker, A. P., Ganz, P. A., Hoverman, J. R., Langdon, R., Lyman, G. H., Meropol, N. J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.2518 · Cited by 655
Effective Treatment of Advanced Multiple Myeloma Refractory to Alkylating Agents
Barlogie, B., Smith, L., & Alexanian, R. (1984) · New England Journal of Medicine · doi:10.1056/nejm198405243102104 · Cited by 641
American Society of Clinical Oncology Guidance Statement: The Cost of Cancer Care
Meropol, N. J., Schrag, D., Smith, T. J., Mulvey, T. M., Langdon, R. M., Blum, D., Ubel, P. A., & Schnipper, L. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.1183 · Cited by 638
Patient-clinician communication: American Society of Clinical Oncology consensus guideline
Gilligan, T., Coyle, N., Frankel, R. M., Berry, D. L., Bohlke, K., Epstein, R. M., Finlay, E., Jackson, V. A., Lathan, C. S., Loprinzi, C. L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.2311 · Cited by 610
IMWG consensus on risk stratification in multiple myeloma
Chng, W. J., Dispenzieri, A., Chim, C.-S., Fonseca, R., Goldschmidt, H., Lentzsch, S., Munshi, N., Palumbo, A., Miguel, J. S., Sonneveld, P., et al. (2014) · Leukemia · doi:10.1038/leu.2013.247 · Cited by 601
Munshi, N. C., Avet-Loiseau, H., Rawstron, A. C., Owen, R. G., Child, J. A., Thakurta, A., Sherrington, P., Samur, M. K., Georgieva, A., Anderson, K. C., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3160 · Cited by 532
Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia
Dusetzina, S. B., Winn, A. N., Abel, G. A., Huskamp, H. A., & Keating, N. L. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.9123 · Cited by 500
Mateos, M.-V., Oriol, A., Martínez-López, J., Gutiérrez, N., Teruel, A.-I., de Paz, R., García-Laraña, J., Bengoechea, E., Martín, A., Mediavilla, J. D., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70187-x · Cited by 458
Tricot, G. J. K., Jagannath, S., Vesole, D. H., Nelson, J., Tindle, S., Miller, L., Cheson, B. D., Crowley, J. J., & Barlogie, B. (1995) · Blood · doi:10.1182/blood.v85.2.588.588 · Cited by 452
Self-citationDaratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
Chari, A., Suvannasankha, A., Fay, J. W., Arnulf, B., Kaufman, J. L., Ifthikharuddin, J. J., Weiss, B. M., Krishnan, A., Lentzsch, S., Comenzo, R., et al. (2017) · Blood · doi:10.1182/blood-2017-05-785246 · Cited by 443
Mateos, M.-V., Richardson, P. G., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.0638 · Cited by 433
Palumbo, A., Bringhen, S., Rossi, D., Cavalli, M., Larocca, A., Ria, R., Offidani, M., Patriarca, F., Nozzoli, C., Guglielmelli, T., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.8216 · Cited by 423
Fried, T. R. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.424 · Cited by 418
Dimopoulos, M. A., Terpos, E., Chanan-Khan, A., Leung, N., Ludwig, H., Jagannath, S., Niesvizky, R., Giralt, S., Fermand, J.-P., Bladé, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.8791 · Cited by 414
Dimopoulos, M. A., Goldschmidt, H., Niesvizky, R., Joshua, D., Chng, W.-J., Oriol, A., Orlowski, R. Z., Ludwig, H., Facon, T., Hajek, R., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30578-8 · Cited by 401
Fermand, J.-P., Katsahian, S., Divine, M., Leblond, V., Dreyfus, F., Macro, M., Arnulf, B., Royer, B., Mariette, X., Pertuiset, E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.0551 · Cited by 399
Neben, K., Lokhorst, H. M., Jauch, A., Bertsch, U., Hielscher, T., van der Holt, B., Salwender, H., Blau, I. W., Weisel, K., Pfreundschuh, M., et al. (2012) · Blood · doi:10.1182/blood-2011-09-379164 · Cited by 356
Kumar, S., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Gastineau, D. A., Litzow, M. R., Fonseca, R., Roy, V, Rajkumar, S. V., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404801 · Cited by 351
Self-citationUpdated Diagnostic Criteria and Staging System for Multiple Myeloma
Rajkumar, S. V. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_159009 · Cited by 350
Blade, J. (2005) · Blood · doi:10.1182/blood-2005-03-1301 · Cited by 335
Spencer, A., Prince, H. M., Roberts, A. W., Prosser, I. W., Bradstock, K. F., Coyle, L., Gill, D. S., Horvath, N., Reynolds, J., & Kennedy, N. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.8573 · Cited by 332
Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials
Lahuerta, J.-J., Paiva, B., Vidriales, M.-B., Cordón, L., Cedena, M.-T., Puig, N., Martinez-Lopez, J., Rosiñol, L., Gutierrez, N. C., Martín-Ramos, M.-L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.2517 · Cited by 317
Gay, F., Oliva, S., Petrucci, M. T., Conticello, C., Catalano, L., Corradini, P., Siniscalchi, A., Magarotto, V., Pour, L., Carella, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00389-7 · Cited by 314
Cavo, M., Pantani, L., Petrucci, M. T., Patriarca, F., Zamagni, E., Donnarumma, D., Crippa, C., Boccadoro, M., Perrone, G., Falcone, A., et al. (2012) · Blood · doi:10.1182/blood-2012-02-408898 · Cited by 308
Palumbo, A., Bringhen, S., Kumar, S. K., Lupparelli, G., Usmani, S., Waage, A., Larocca, A., van der Holt, B., Musto, P., Offidani, M., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70609-0 · Cited by 289
Self-citationvan de Velde, H. J. K., Liu, X., Chen, G., Cakana, A., Deraedt, W., & Bayssas, M. (2007) · Haematologica · doi:10.3324/haematol.11534 · Cited by 283
Moreau, P., Hulin, C., Macro, M., Caillot, D., Chaleteix, C., Roussel, M., Garderet, L., Royer, B., Brechignac, S., Tiab, M., et al. (2016) · Blood · doi:10.1182/blood-2016-01-693580 · Cited by 278
Krishnan, A., Pasquini, M. C., Logan, B., Stadtmauer, E. A., Vesole, D. H., Alyea, E., Antin, J. H., Comenzo, R., Goodman, S., Hari, P., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70243-1 · Cited by 274
Self-citationEngelhardt, M., Domm, A.-S., Dold, S. M., Ihorst, G., Reinhardt, H., Zober, A., Hieke, S., Baayen, C., Müller, S. J., Einsele, H., et al. (2017) · Haematologica · doi:10.3324/haematol.2016.162693 · Cited by 274
Fayers, P. M., Palumbo, A., Hulin, C., Waage, A., Wijermans, P., Beksaç, M., Bringhen, S., Mary, J.-Y., Gimsing, P., Termorshuizen, F., et al. (2011) · Blood · doi:10.1182/blood-2011-03-341669 · Cited by 272
Facon, T., Dimopoulos, M. A., Dispenzieri, A., Catalano, J. V., Belch, A., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N. J., et al. (2018) · Blood · doi:10.1182/blood-2017-07-795047 · Cited by 271
Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics
Kumar, S., Fonseca, R., Ketterling, R. P., Dispenzieri, A., Lacy, M. Q., Gertz, M. A., Hayman, S. R., Buadi, F. K., Dingli, D., Knudson, R. A., et al. (2012) · Blood · doi:10.1182/blood-2011-11-390658 · Cited by 253
Self-citationPatient and Plan Characteristics Affecting Abandonment of Oral Oncolytic Prescriptions
Streeter, S. B., Schwartzberg, L., Husain, N., & Johnsrud, M. (2011) · Journal of Oncology Practice · doi:10.1200/jop.2011.000316 · Cited by 248
Dimopoulos, M. A., Gay, F., Schjesvold, F., Beksac, M., Hajek, R., Weisel, K. C., Goldschmidt, H., Maisnar, V., Moreau, P., Min, C. K., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)33003-4 · Cited by 237
(2008) · Cited by 225
Avet-Loiseau, H., Attal, M., Campion, L., Caillot, D., Hulin, C., Marit, G., Stoppa, A.-M., Voillat, L., Wetterwald, M., Pegourie, B., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.5726 · Cited by 224
Palumbo, A., Bringhen, S., Larocca, A., Rossi, D., Di Raimondo, F., Magarotto, V., Patriarca, F., Levi, A., Benevolo, G., Vincelli, I. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.0023 · Cited by 211
Regelink, J. C., Minnema, M. C., Terpos, E., Kamphuis, M. H., Raijmakers, P. G., Pieters – van den Bos, I. C., Heggelman, B. G. F., Nievelstein, R., Otten, R. H. J., van Lammeren – Venema, D., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12346 · Cited by 211
Landgren, O., Devlin, S., Boulad, M., & Mailankody, S. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2016.222 · Cited by 195
Gahrton, G., Iacobelli, S., Björkstrand, B., Hegenbart, U., Gruber, A., Greinix, H., Volin, L., Narni, F., Carella, A. M., Beksac, M., et al. (2013) · Blood · doi:10.1182/blood-2012-11-469452 · Cited by 191
San-Miguel, J. F., Richardson, P. G., Sonneveld, P., Schuster, M. W., Irwin, D., Stadtmauer, E. A., Facon, T., Harousseau, J.-L., Ben-Yehuda, D., Lonial, S., et al. (2008) · Leukemia · doi:10.1038/sj.leu.2405087 · Cited by 185
Reece, D., Song, K. W., Fu, T., Roland, B., Chang, H., Horsman, D. E., Mansoor, A., Chen, C., Masih-Khan, E., Trieu, Y., et al. (2009) · Blood · doi:10.1182/blood-2008-12-193458 · Cited by 185
van Rhee, F., Bolejack, V., Hollmig, K., Pineda-Roman, M., Anaissie, E., Epstein, J., Shaughnessy, J. D., Zangari, M., Tricot, G., Mohiuddin, A., et al. (2007) · Blood · doi:10.1182/blood-2007-01-067728 · Cited by 184
Shiffman, R. N., Michel, G., Rosenfeld, R. M., & Davidson, C. (2012) · Journal of the American Medical Informatics Association · doi:10.1136/amiajnl-2011-000172 · Cited by 184
Rawstron, A. C., Gregory, W. M., de Tute, R. M., Davies, F. E., Bell, S. E., Drayson, M. T., Cook, G., Jackson, G. H., Morgan, G. J., Child, J. A., et al. (2015) · Blood · doi:10.1182/blood-2014-07-590166 · Cited by 178
Facon, T. (2006) · Blood · doi:10.1182/blood-2005-04-1588 · Cited by 178
Roussel, M., Moreau, P., Huynh, A., Mary, J.-Y., Danho, C., Caillot, D., Hulin, C., Fruchart, C., Marit, G., Pégourié, B., et al. (2010) · Blood · doi:10.1182/blood-2009-06-229658 · Cited by 171
Engelhardt, M., Dold, S. M., Ihorst, G., Zober, A., Moller, M., Reinhardt, H., Hieke, S., Schumacher, M., & Wasch, R. (2016) · Haematologica · doi:10.3324/haematol.2016.148189 · Cited by 171
Popat, U., Saliba, R., Thandi, R., Hosing, C., Qazilbash, M., Anderlini, P., Shpall, E., McMannis, J., Körbling, M., Alousi, A., et al. (2009) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2009.02.011 · Cited by 169
Giralt, S., Garderet, L., Durie, B., Cook, G., Gahrton, G., Bruno, B., Hari, P., Lokhorst, H., McCarthy, P., Krishnan, A., et al. (2015) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2015.09.016 · Cited by 165
Self-citationDimopoulos, M. A., Palumbo, A., Corradini, P., Cavo, M., Delforge, M., Di Raimondo, F., Weisel, K. C., Oriol, A., Hansson, M., Vacca, A., et al. (2016) · Blood · doi:10.1182/blood-2016-02-700872 · Cited by 165
Kapoor, P., Kumar, S. K., Dispenzieri, A., Lacy, M. Q., Buadi, F., Dingli, D., Russell, S. J., Hayman, S. R., Witzig, T. E., Lust, J. A., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.0086 · Cited by 162
Self-citationBaz, R. C., Martin, T. G., Lin, H.-Y., Zhao, X., Shain, K. H., Cho, H. J., Wolf, J. L., Mahindra, A., Chari, A., Sullivan, D. M., et al. (2016) · Blood · doi:10.1182/blood-2015-11-682518 · Cited by 159
Self-citationCommunity-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens
Niesvizky, R., Flinn, I. W., Rifkin, R. M., Gabrail, N. Y., Charu, V., Clowney, B., Essell, J. H., Gaffar, Y., Warr, T. A., Neuwirth, R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.7618 · Cited by 156
Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients
Paiva, B., Cedena, M., Puig, N., Arana, P., Vídriales, M., Cordón, L., Flores-Montero, J. A., Gutierrez, N. C., Martín-Ramos, M.-L., Martínez‐López, J., et al. (2016) · Blood · doi:10.1182/blood-2016-03-705319 · Cited by 155
Cook, G., Ashcroft, A. J., Cairns, D. A., Williams, C. D., Brown, J. M., Cavenagh, J. D., Snowden, J. A., Parrish, C., Yong, K., Cavet, J., et al. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(16)30049-7 · Cited by 153
Cook, G., Williams, C. D., Brown, J. M., Cairns, D. A., Cavenagh, J. D., Snowden, J. A., Ashcroft, A. J., Fletcher, M., Parrish, C., Yong, K., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70245-1 · Cited by 152
Palumbo, A., Gay, F., Cavallo, F., Di Raimondo, F., Larocca, A., Hardan, I., Nagler, A., Petrucci, M. T., Hajek, R., Pezzatti, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.2466 · Cited by 150
Mai, E. K., Bertsch, U., Dürig, J., Kunz, C., Haenel, M., Blau, I. W., Munder, M., Jauch, A. T., Schurich, B., Hielscher, T., et al. (2015) · Leukemia · doi:10.1038/leu.2015.80 · Cited by 146
Stewart, A. K., Trudel, S., Bahlis, N. J., White, D. J., Sabry, W., Belch, A. R., Reiman, T., Roy, J., Shustik, C., Kovacs, M. J., et al. (2013) · Blood · doi:10.1182/blood-2012-09-451872 · Cited by 142
Self-citationMellqvist, U., Gimsing, P., Hjertner, Ø., Lenhoff, S., Laane, E., Remes, K., Steingrímsdóttir, H., Abildgaard, N., Ahlberg, L., Blimark, C. H., et al. (2013) · Blood · doi:10.1182/blood-2012-11-464503 · Cited by 138
Dimopoulos, M. A., Lonial, S., White, D. J., Moreau, P., Palumbo, A. P., Miguel, J. F. S., Shpilberg, O., Anderson, K. C., Grosicki, S., Špıčka, I., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14787 · Cited by 138
Richardson, P. G. G., Hungria, V., Yoon, S., Beksaç, M., Dimopoulos, M. A., Elghandour, A., Wiktor-Jędrzejczak, W., Guenther, A., Nakorn, T. N., Siritanaratkul, N., et al. (2015) · Blood · doi:10.1182/blood-2015-09-665018 · Cited by 133
Avet‐Loiseau, H., Fonseca, R., Siegel, D. S. D., Dimopoulos, M. A., Špıčka, I., Masszi, T., Hájek, R., Rosiñol, L., Goranova-Marinova, V. S., Mihaylov, G. G., et al. (2016) · Blood · doi:10.1182/blood-2016-03-707596 · Cited by 126
Zweegman, S., van der Holt, B., Mellqvist, U., Salomo, M., Bos, G. M. J., Levin, M., Visser-Wisselaar, H. A., Hansson, M., van der Velden, A. W. G., Deenik, W., et al. (2016) · Blood · doi:10.1182/blood-2015-11-679415 · Cited by 124
Moreau, P., Attal, M., Pegourié, B., Planche, L., Hulin, C., Facon, T. T. F., Stoppa, A., Fuzibet, J., Grosbois, B., Doyen, C., et al. (2010) · Blood · doi:10.1182/blood-2010-08-300863 · Cited by 123
van Beurden-Tan, C. H. Y., Franken, M. G., Blommestein, H. M., Groot, C. A. U., & Sonneveld, P. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.1663 · Cited by 123
Kumar, S. K., Lacy, M. Q., Dispenzieri, A. A., Buadi, F. K., Hayman, S. R., Dingli, D., Gay, F., Sinha, S., Leung, N., Hogan, W. J., et al. (2011) · Cancer · doi:10.1002/cncr.26422 · Cited by 122
Self-citationAuner, H. W., Szydlo, R., Hoek, J., Goldschmidt, H., Stoppa, A., Morgan, G. J., Moreau, P., Attal, M., Marit, G., Russell, N. H., et al. (2014) · Bone Marrow Transplantation · doi:10.1038/bmt.2014.255 · Cited by 122
Giaccone, L., Storer, B. E., Patriarca, F. F., Rotta, M., Sorasio, R., Allione, B., Carnevale‐Schianca, F., Festuccia, M. B., Brunello, L., Omedè, P., et al. (2011) · Blood · doi:10.1182/blood-2011-03-339945 · Cited by 122
Avet‐Loiseau, H., Hulin, C., Campion, L., Rodon, P., Marit, G., Attal, M., Royer, B., Dib, M., Voillat, L., Bouscary, D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.2598 · Cited by 118
Racial disparities in treatment use for multiple myeloma
Fiala, M. A., & Wildes, T. M. (2017) · Cancer · doi:10.1002/cncr.30526 · Cited by 113
Self-citationLahuerta, J. J., Mateos, M. V., Martínez‐López, J., Grande, C., de la Rubia, J., Rosiñol, L., Sureda, A. M., García‐Laraña, J., Díaz-Mediavilla, J., Hernández‐Garcia, M. T., et al. (2010) · Haematologica · doi:10.3324/haematol.2010.028027 · Cited by 110
Stadtmauer, E. A., Weber, D. M., Niesvizky, R., Belch, A., Prince, M. H., Miguel, J. F. S., Facon, T. T. F., Olesnyckyj, M., Yu, Z., Zeldis, J. B., et al. (2009) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2009.01257.x · Cited by 106
Mateos, M., Oriol, A., Martínez‐López, J., Teruel, A. I., de la Guía, A. L., López, J., Bengoechea, E., Pérez, M., Martínez, R., Palomera, L., et al. (2014) · Blood · doi:10.1182/blood-2014-05-573733 · Cited by 104
Elderly patients with multiple myeloma: towards a frailty approach?
Zweegman, S., Engelhardt, M. M., & Larocca, A. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000395 · Cited by 102
Impact of early relapse after auto-SCT for multiple myeloma
Kumar, S. K., Mahmood, S., Lacy, M. Q., Dispenzieri, A. A., Hayman, S. R., Buadi, F. K., Dingli, D., Rajkumar, S. V., Litzow, M. R., & Gertz, M. A. (2008) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.180 · Cited by 99
Self-citationPalumbo, A., Bringhen, S., Bruno, B., Falcone, A. P., Liberati, A. M., Grasso, M., Ria, R., Pisani, F., Cangialosi, C., Caravita, T., et al. (2009) · Blood · doi:10.1182/blood-2009-09-241737 · Cited by 99
Niesvizky, R., Richardson, P. G. G., Rajkumar, S. V., Coleman, M., Rosiñol, L., Sonneveld, P., Schuster, M. W., Irwin, D. H., Stadtmauer, E. A., Facon, T. T. F., et al. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07303.x · Cited by 98
Magarotto, V., Bringhen, S., Offidani, M., Benevolo, G., Patriarca, F. F., Mina, R., Falcone, A. P., Paoli, L. D., Pietrantuono, G., Gentili, S., et al. (2016) · Blood · doi:10.1182/blood-2015-08-662627 · Cited by 93
Stewart, A. K., Jacobus, S. J., Fonseca, R., Weiss, M., Callander, N. S., Chanan-Khan, A. A., & Rajkumar, S. V. (2015) · Blood · doi:10.1182/blood-2014-12-613927 · Cited by 91
Delforge, M., Minuk, L. A., Eisenmann, J.-C., Arnulf, B., Canepa, L., Fragasso, A., Leyvraz, S., Langer, C., Ezaydi, Y., Vogl, D. T., et al. (2015) · Haematologica · doi:10.3324/haematol.2014.120121 · Cited by 90
Mateos, M., Hernández‐Rivas, J. M., Hernández, M., Gutierrez, N. C., Palomera, L., Fuertes, M., Garcia-Sanchez, P., Lahuerta, J. J., de la Rubia, J., Terol, M. J., et al. (2008) · Haematologica · doi:10.3324/haematol.12106 · Cited by 86
Hulin, C., Belch, A. R., Shustik, C., Petrucci, M. T., Dührsen, U., Lu, J., Song, K., Rodon, P., Pegourié, B., Garderet, L., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.7295 · Cited by 83
Jones, J. R., Cairns, D. A., Gregory, W. M., Collett, C., Pawlyn, C., Sigsworth, R., Striha, A., Henderson, R., Kaiser, M., Jenner, M. W., et al. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.114 · Cited by 83
Moreau, P., Joshua, D. E., Chng, W.-J., Palumbo, A. P., Goldschmidt, H., Hájek, R., Facon, T. T. F., Ludwig, H., Pour, L., Niesvizky, R., et al. (2016) · Leukemia · doi:10.1038/leu.2016.186 · Cited by 82
Garderet, L., Beohou, E., Caillot, D., Stoppa, A. M., Touzeau, C., Chrétien, M. L., Karlin, L., Moreau, P., Fontan, J., Blaise, D., et al. (2016) · Haematologica · doi:10.3324/haematol.2016.150334 · Cited by 79
Value and Cost of Myeloma Therapy
Rajkumar, S. V. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_200867 · Cited by 77
Usmani, S. Z., Sexton, R. E., Hoering, A., Heuck, C. J., Nair, B. P., Waheed, S., Alsayed, Y. M., Chauhan, N., Ahmad, N., Atrash, S., et al. (2012) · Blood · doi:10.1182/blood-2012-04-421883 · Cited by 75
Dimopoulos, M. A., Weisel, K. C., Song, K., Delforge, M., Karlin, L., Goldschmidt, H., Moreau, P., Baños, A., Oriol, A., Garderet, L., et al. (2015) · Haematologica · doi:10.3324/haematol.2014.117077 · Cited by 73
Vij, R., Kumar, S. K., Zhang, M., Zhong, X., Huang, J., Dispenzieri, A. A., Abidi, M. H., Bird, J. M., Freytes, C. O., Gale, R. P., et al. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.10.023 · Cited by 72
Self-citationArmeson, K. E., Hill, E. G., & Costa, L. J. (2012) · Bone Marrow Transplantation · doi:10.1038/bmt.2012.173 · Cited by 72
Rosiñol, L., Oriol, A., Teruel, A. I., de la Guía, A. L., Blanchard, M., de la Rubia, J., Granell, M., Sampol, M., Palomera, L., González, Y., et al. (2017) · Leukemia · doi:10.1038/leu.2017.35 · Cited by 71
Dimopoulos, M. A., Stewart, A. K., Masszi, T., Špıčka, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S. D., Mihaylov, G. G., Goranova-Marinova, V. S., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14549 · Cited by 71
Mateos, M., Richardson, P. G. G., Dimopoulos, M. A., Palumbo, A. P., Anderson, K. C., Shi, H., Elliott, J., Dow, E., de Velde, H. J. V., Niculescu, L., et al. (2015) · American Journal of Hematology · doi:10.1002/ajh.23933 · Cited by 70
Bonanad, S., de la Rubia, J., Gironella, M., Persona, E. P., González, B., Fernández-Lago, C., Arnán, M., Zudaire, I., Hernández‐Rivas, J., Soler, A., et al. (2015) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2015.03.003 · Cited by 69
Delforge, M., Dhawan, R., Robinson, D., Meunier, J., Regnault, A., Esseltine, D.-L. W., Cakana, A., de Velde, H. J. V., Richardson, P. G. G., & Miguel, J. F. S. (2012) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2012.01788.x · Cited by 67
Mai, E. K., Benner, A., Bertsch, U., Brossart, P., Hänel, A., Kunzmann, V., Naumann, R., Neben, K., Egerer, G., Ho, A. D., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.13994 · Cited by 67
Mahindra, A. K., Hari, P., Fraser, R. A., Fei, M., Huang, J., Berdeja, J. G., Callander, N. S., Costa, L. J., Díaz, M. Á., Freytes, C. O., et al. (2017) · Bone Marrow Transplantation · doi:10.1038/bmt.2017.198 · Cited by 65
Self-citationComplete response in multiple myeloma
Kyle, R. A., Leong, T. L., Li, S., Oken, M. M., Kay, N. E., Ness, B. V., & Greipp, P. R. (2006) · Cancer · doi:10.1002/cncr.21804 · Cited by 62
Chng, W.-J., Goldschmidt, H., Dimopoulos, M. A., Moreau, P., Joshua, D. E., Palumbo, A. P., Facon, T. T. F., Ludwig, H., Pour, L., Niesvizky, R., et al. (2016) · Leukemia · doi:10.1038/leu.2016.390 · Cited by 60
Botta, C., Ciliberto, D., Rossi, M., Staropoli, N., Cucè, M., Galeano, T., Tagliaferri, P., & Tassone, P. (2017) · Blood Advances · doi:10.1182/bloodadvances.2016003905 · Cited by 60
Autologous retransplantation for patients with recurrent multiple myeloma
Sellner, L., Heiß, C., Benner, A., Raab, M. S., Hillengaß, J., Hose, D., Lehners, N., Egerer, G., Ho, A. D., Goldschmidt, H., et al. (2013) · Cancer · doi:10.1002/cncr.28104 · Cited by 59
Maiolino, Â., Hungria, V., Garnica, M., Oliveira-Duarte, G. B., de Oliveira, L. C. O., Mercante, D., MIRANDA, E. C. M., Quero, A. A., Peres, A. L., Barros, J. C., et al. (2012) · American Journal of Hematology · doi:10.1002/ajh.23274 · Cited by 59
Khan, M. L., Reeder, C. B., Kumar, S. K., Lacy, M. Q., Reece, D. E., Dispenzieri, A. A., Gertz, M. A., Greipp, P. R., Hayman, S. R., Zeldenhurst, S., et al. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08949.x · Cited by 55
Self-citationD(T) PACE as salvage therapy for aggressive or refractory multiple myeloma
Gerrie, A. S., Mikhael, J. R., Cheng, L., Jiang, H., Kukreti, V., Panzarella, T., Reece, D. E., Stewart, K., Trieu, Y., Trudel, S., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12325 · Cited by 55
Self-citationLeiba, M., Kedmi, M., Duek, A., Freidman, T., Weiss, M., Leiba, R., Nagler, A., & Avigdor, A. (2014) · British Journal of Haematology · doi:10.1111/bjh.12946 · Cited by 52
Miguel, J. F. S., Weisel, K. C., Song, K., Delforge, M., Karlin, L., Goldschmidt, H., Moreau, P., Baños, A., Oriol, A., Garderet, L., et al. (2015) · Haematologica · doi:10.3324/haematol.2015.125864 · Cited by 52
Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival
Chin, M., Sive, J. I., Allen, C. G., Roddie, C., Chavda, S. J., Smith, D., Blombery, P. A., Jones, K. L., Ryland, G. L., Popat, R., et al. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.76 · Cited by 52
Undertreatment of Older Patients With Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies
Fakhri, B., Fiala, M. A., Tuchman, S. A., & Wildes, T. M. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.01.005 · Cited by 51
Self-citationOrlowski, R. Z., Nagler, A., Sonneveld, P., Bladé, J., Hájek, R., Spencer, A. G., Robak, T., Dmoszyńska, A., Horvath, N., Špıčka, I., et al. (2016) · Cancer · doi:10.1002/cncr.30026 · Cited by 50
Kharfan‐Dabaja, M. A., Hamadani, M., Reljic, T., Nishihori, T., Bensinger, W., Djulbegović, B., & Kumar, A. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-2 · Cited by 48
Bodge, M. N., Reddy, S., Thompson, M. S., & Savani, B. N. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.02.013 · Cited by 47
Larocca, A., Bringhen, S., Petrucci, M. T., Oliva, S., Falcone, A. P., Caravita, T., Villani, O., Benevolo, G., Liberati, A. M., Morabito, F., et al. (2016) · Leukemia · doi:10.1038/leu.2016.36 · Cited by 43
Olszewski, A. J., Dusetzina, S. B., Eaton, C. B., Davidoff, A. J., & Trivedi, A. N. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.2447 · Cited by 43
Nooka, A. K., Kaufman, J. L., Behera, M., Langston, A. A., Waller, E. K., Flowers, C. R., Gleason, C. L., Boise, L., & Lonial, S. (2013) · Cancer · doi:10.1002/cncr.28325 · Cited by 42
Zhang, T., Wang, S., Lin, T.-F., Xie, J., Zhao, L., Liang, Z., Li, Y., & Jiang, J. (2017) · Oncotarget · doi:10.18632/oncotarget.16987 · Cited by 42
Hari, P., Romanus, D., Palumbo, A. P., Luptakova, K., Rifkin, R. M., Tran, L. M., Raju, A., Farrelly, E., Noga, S. J., Blazer, M. A., et al. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.12.012 · Cited by 42
Dimopoulos, M. A., Cheung, M. C., Roussel, M., Liu, T., Gamberi, B., Kolb, B., Derigs, H. G., Eom, H., Merzoug, K. B., Lenain, P., et al. (2015) · Haematologica · doi:10.3324/haematol.2015.133629 · Cited by 40
Self-citationCho, Y., Sborov, D., Lamprecht, M., Li, J., Wang, J., Hade, E. M., Gao, Y., Tackett, K., Williams, N. O., Benson, D., et al. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.644 · Cited by 37
Straka, C., Liebisch, P., Salwender, H. J., Hennemann, B., Metzner, B., Knop, S. T., Adler-Reichel, S., Gerecke, C., Wandt, H., Bentz, M., et al. (2016) · Haematologica · doi:10.3324/haematol.2016.151860 · Cited by 36
Tandon, N., Rajkumar, S. V., LaPlant, B. R., Pettinger, A. M., Lacy, M. Q., Dispenzieri, A. A., Buadi, F. K., Gertz, M. A., Hayman, S. R., Leung, N., et al. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.13 · Cited by 34
Self-citationBensinger, W., Becker, P. S., Gooley, T. A., Chauncey, T. R., Maloney, D. G., Gopal, A. K., Green, D. J., Press, O. W., Lill, M., Ifthikharuddin, J. J., et al. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.211 · Cited by 33
de Velde, H. J. V., Londhe, A., Ataman, Ö., Johns, H. L., Hill, S., Landers, E., & Berlin, J. A. (2016) · European Journal Of Haematology · doi:10.1111/ejh.12829 · Cited by 31
Sun, Z., Zheng, F., Wu, S., Liu, Y., Guo, H., & Liu, Y. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.03.018 · Cited by 30
Fixed duration vs continuous therapy in multiple myeloma
Ludwig, H., & Zojer, N. (2017) · Hematology · doi:10.1182/asheducation-2017.1.212 · Cited by 30
Avet‐Loiseau, H., & Facon, T. T. F. (2018) · Leukemia · doi:10.1038/s41375-018-0098-9 · Cited by 27
Management of disease- and treatment-related complications in patients with multiple myeloma
Gay, F., & Palumbo, A. (2010) · Medical Oncology · doi:10.1007/s12032-010-9542-z · Cited by 25
Qiao, S.-K., Guo, X., Ren, J., & Ren, H. (2015) · Chinese Medical Journal · doi:10.4103/0366-6999.156134 · Cited by 23
Weisel, K. C., Dimopoulos, M. A., Moreau, P., Lacy, M. Q., Song, K., Delforge, M., Karlin, L., Goldschmidt, H., Baños, A., Oriol, A., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.137083 · Cited by 22
Self-citationFurther psychometric validation of the GAH scale: Responsiveness and effect size
Cruz-Jentoft, A. J., González, B., de la Rubia, J., et al. (2016) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2016.12.008 · Cited by 22
Wildes, T. M., & Anderson, K. C. (2018) · Hematology · doi:10.1182/asheducation-2018.1.88 · Cited by 22
Self-citationShah, J. J., Bladé, J., Sonneveld, P., Harousseau, J., Lantz, K. C., Londhe, A., Lowery, C., & Orlowski, R. Z. (2011) · Cancer · doi:10.1002/cncr.25937 · Cited by 21
Gentile, M., Magarotto, V., Offidani, M., Musto, P., Bringhen, S., Petrucci, M. T., Gay, F., Larocca, A., Uccello, G., Petrungaro, A., et al. (2016) · American Journal of Hematology · doi:10.1002/ajh.24621 · Cited by 21
Bahlis, N. J., Corso, A., Mügge, L.-O., Shen, Z.-X., Desjardins, P., Stoppa, A.-M., Decaux, O., de Revel, T., Granell, M., Marit, G., et al. (2017) · Leukemia · doi:10.1038/leu.2017.111 · Cited by 21
Kropff, M. H., Vogel, M., Bisping, G., Schlag, R., Weide, R., Knauf, W. U., Fiechtner, H., Kojouharoff, G., Kremers, S., & Berdel, W. E. (2017) · Annals of Hematology · doi:10.1007/s00277-017-3065-z · Cited by 20
Time to plateau as a predictor of survival in newly diagnosed multiple myeloma
Mellors, P. W., Binder, M., Buadi, F. K., Lacy, M. Q., Gertz, M. A., Dispenzieri, A. A., Hayman, S. R., Kapoor, P., Gonsalves, W. I., Hwa, Y. L., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25113 · Cited by 18
Self-citationChakraborty, R., Muchtar, E., Kumar, S. K., Buadi, F. K., Dingli, D., Dispenzieri, A. A., Hayman, S. R., Hogan, W. J., Kapoor, P., Lacy, M. Q., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.15244 · Cited by 18
Self-citationZou, Y., Ma, X., Yu, H., Hu, C., Fan, L., & Ran, X. (2016) · Oncotarget · doi:10.18632/oncotarget.10768 · Cited by 16
Łopuch, S., Kawalec, P., & Wiśniewska, N. (2014) · Hematology · doi:10.1179/1607845414y.0000000159 · Cited by 14
Liu, J., Sun, C., Tang, L. V., Wu, Y., Wang, Q., Hu, B., & Hu, Y. (2016) · Scientific Reports · doi:10.1038/srep27361 · Cited by 13
Liu, J., Yang, H. J., Liang, X., Wang, Y., Hou, J., Liu, Y., Wang, J., & Zhou, F. (2017) · Oncotarget · doi:10.18632/oncotarget.18722 · Cited by 13
Zago, M., Oehrlein, K., Rendl, C., Hahn‐Ast, C., Kanz, L., & Weisel, K. C. (2014) · Annals of Hematology · doi:10.1007/s00277-014-2149-2 · Cited by 12
Ozaki, S., Hata, H., Abe, M., Saitoh, T., Hanamura, I., Yano, H., Sunami, K., Kosugi, H., Sawamura, M., Nakazato, T., et al. (2016) · Annals of Hematology · doi:10.1007/s00277-016-2661-7 · Cited by 4
Cited by
Voorhees, P. M., Kaufman, J. L., Laubach, J., Sborov, D. W., Reeves, B., Rodriguez, C., Chari, A., Silbermann, R., Costa, L. J., Anderson, L. D., et al. (2020) · Blood · doi:10.1182/blood.2020005288 · Cited by 693
Self-citationCavo, M., Gay, F., Beksac, M., Pantani, L., Petrucci, M. T., Dimopoulos, M. A., Dozza, L., van der Holt, B., Zweegman, S., Oliva, S., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30099-5 · Cited by 381
Pillarisetti, K., Powers, G., Luistro, L., Babich, A., Baldwin, E., Li, Y., Zhang, X., Mendonça, M., Majewski, N., Nanjunda, R., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002393 · Cited by 144
“Within the past decade, the introduction of proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies has changed the landscape of myeloma management, leading to improved disease control and prolonged survival.(3-12) Despite these therapeutic advances, nearly all patients will eventually relapse”
BackgroundFonseca, R., Usmani, S. Z., Mehra, M., Slavcev, M., He, J., Cote, S., Lam, A., Ukropec, J., Maiese, E. M., Nair, S., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-07503-y · Cited by 127
Genome-wide somatic alterations in multiple myeloma reveal a superior outcome group
Samur, M. K., Aktas Samur, A., Fulciniti, M., Szalat, R., Han, T., Shammas, M., Richardson, P., Magrangeas, F., Minvielle, S., Corre, J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00461 · Cited by 70
Metadata
- Authors
- Mikhael, J., Ismaila, N., Cheung, M. C., Costello, C., Dhodapkar, M. V., Kumar, S., Lacy, M., Lipe, B., Little, R. F., Nikonova, A., Omel, J., Peswani, N., Prica, A., Raje, N., Seth, R., Vesole, D. H., Walker, I., Whitley, A., Wildes, T. M., Wong, S. W., & Martin, T.
- Venue
- Journal of Clinical Oncology
- Published
- 2019-05-10
- Volume
- 37
- Issue
- 14
- Pages
- 1228-1263
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2928272073
- Cited by
- 331
- References
- 179
- FWCI
- 26.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.